Hims & Hers Health (NYSE: HIMS) Shares Fell Approximately 6% After Hours Monday and Extended the Decline Into Tuesday August 11 Trading Despite Q2 2026 Revenue of $753.2 Million (+38% YoY, Beating $698.9M Consensus) and Q3 Guidance of $890 Million (+12.4% Above Consensus); GAAP Loss of $0.37 per Share Was Well Below Analyst Estimates, and Gross Margin Compression to 64% (From 76% Year-Ago) Hit Its Fourth Consecutive Quarter of Decline as the Compounded-to-Branded GLP-1 Pivot Continued to Drag Unit Economics; Q2 Net Loss of $86.3 Million Versus $42.5 Million Net Income in Q2 2025
Hims & Hers Health (NYSE: HIMS) shares fell approximately 6% after hours Monday and extended the decline into Tuesday August 11, 2026 trading despite Q2 2026 revenue of $753.2 million (+38% year-over-year, beating $698.9 million consensus) and Q3 guidance of $890 million at the midpoint (+12.4% above analyst expectations). The GAAP loss of $0.37 per share ran well below analyst estimates, and gross margin compression to 64% (from 76% year-ago) hit its fourth consecutive quarter of decline. Q2 net loss reached $86.3 million versus $42.5 million net income in Q2 2025. The compounded-to-branded GLP-1 pivot through the Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound, Mounjaro) commercial partnerships since Q1 2026 continues to drag unit economics. Full-year 2026 guidance was raised to $3.1-3.3 billion revenue and $275-325 million Adjusted EBITDA. The market appears to be pricing the compounded-to-branded pivot as a durable margin drag rather than a transitory transition; the July 29 FTC lawsuit alleging consumer health data sharing with Meta and Snap plus unauthorized billing charges remains a substantive overhang. Chief Medical Officer Dr. Anant Vinjamoori's July 23 PCAC harm-reduction testimony framing continues to shape the peptide-strategy narrative for the stock.